InvestorsHub Logo
Post# of 251714
Next 10
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 201629

Tuesday, 06/28/2016 11:15:46 AM

Tuesday, June 28, 2016 11:15:46 AM

Post# of 251714
FDA approves GILD’s Epclusa (SOF/VEL)—list price=$74K for 12 weeks:

https://t.co/4BL2aB7Bqo

The approval is nominally for all HCV genotypes; however (as previously noted on this board), the product is primarily intended for GT3 patients. There is no 8-week treatment option.

Today is the PDUFA date.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.